Work

Mirvetuximab soravtansine (MIRV) in patients with platinum-resistant ovarian cancer with high folate receptor alpha (FRα) expression: Evaluation of sequence of therapy on anti-tumor activity in the SORAYA study (002)

Year: 2023

Type: article

Source: Gynecologic Oncology

DOI: 10.1016/j.ygyno.2023.06.468

Authors: Robert Coleman, Ana Oaknin, Sandro Pignata, Hannelore Denys, Nicoletta Colombo, Toon Van Gorp, Jason Konner, Margarita Romeo Marin, Philipp Harter, Conleth Murphy, Brooke Esteves, Michael Method, Domenica Lorusso, Ursula Matulonis

Institutions: The US Oncology Network, Vall d'Hebron Institute of Oncology, Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale", Ghent University Hospital, European Institute of Oncology, Universitair Ziekenhuis Leuven, Memorial Sloan Kettering Cancer Center, Institut Català d'Oncologia, Hospital Universitari Germans Trias i Pujol, Kliniken Essen-Mitte, Bon Secours Hospital Cork, ImmunoGen (United States), Agostino Gemelli University Polyclinic, Dana-Farber Cancer Institute

Language: English

Topic: Ovarian cancer diagnosis and treatment

Subfield: Reproductive Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W4386948810

FWCI: 0.479

Cites:

Cited by: 2

Related to: 10